// App-Quantinova.ai

1381 : Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Researchers

Presenter

  • Sara Bringhen

Principal Investigators

  • Ludek Pour

  • Reuben Benjamin

  • Sebastian Grosicki

  • Chang-Ki Min

  • Danielle Leao Cordeiro De Farias

  • Alexander Vorog

  • Richard J Labotka

  • Bingxia Wang

  • Dasha Cherepanov

  • Lauren E. Cain

  • Sudhakar Manne

  • S. Vincent Rajkumar

  • Meletios A. Dimopoulos

Medical Centers

  • Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Torino, Italy

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Department of Hematology and Cancer Prevention,Health Sciences Faculty, Medical University of Silesia,Katowice,Poland

  • Department of Blood and Marrow Transplantation, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South)

  • Hospital A Beneficência Portuguesa de São Paulo,São Paulo,Brazil

  • Hospital das Clinicas,Universidade Federal de Goiás (UFG),Goiânia Goiás,Brazil

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

Locations

  • Italy

  • Czech Republic

  • United Kingdom

  • Poland

  • Republic of South Korea

  • Brazil

  • United States

  • Greece

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02312258

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved